Welcome to our dedicated page for Editas Medicine news (Ticker: EDIT), a resource for investors and traders seeking the latest updates and insights on Editas Medicine stock.
Editas Medicine, Inc. develops genome editing medicines using CRISPR systems for serious diseases. Company news centers on its in vivo pipeline, including EDIT-401, an LDLR-targeted development candidate designed to treat hyperlipidemia by increasing LDLR protein expression and reducing LDL cholesterol.
Recurring updates include quarterly financial results, business highlights, scientific conference presentations, preclinical data for EDIT-401, intellectual property developments involving CRISPR/Cas9 patent interference, and investor conference participation. The company also reports on pipeline prioritization and its licensed Cas12a and Cas9 patent estates for human medicines.
Editas Medicine (EDIT) granted an inducement stock option award to its newly appointed Chief Medical Officer, Daniel Ory, M.D., in accordance with Nasdaq Listing Rule 5635(c)(4).
The option covers up to 950,000 shares of Editas Medicine common stock at an exercise price of $3.03 per share, equal to the closing price on the grant date. The award vests over four years, with 25% of the shares vesting on the 15th day of the month immediately following the first anniversary of Dr. Ory’s start date, and the remaining 75% vesting ratably at the end of each subsequent month, contingent on his continued service with the company.
Editas Medicine (EDIT) appointed Dan Ory, M.D., as Chief Medical Officer, effective September 8, 2026, to lead its clinical development organization.
Dr. Ory has more than 25 years of experience in biotechnology leadership, cardiovascular medicine, and genetic medicine development. He will oversee clinical strategy and operations as Editas advances EDIT-401, its lead in vivo gene editing candidate for the potential treatment of hyperlipidemia, toward first-in-human studies, while supporting the broader pipeline. His background includes CMO roles at Arbor Biotechnologies and Casma Therapeutics and a long academic career in cholesterol metabolism and cardiovascular disease research at Washington University School of Medicine.
Editas Medicine (Nasdaq: EDIT) announced that management will participate in two September investor conferences: the Wells Fargo Healthcare Conference on September 8, 2026 at 4:30 p.m. ET in Boston, and the Cantor Global Healthcare Conference on September 10, 2026 at 3:55 p.m. ET in New York.
Both appearances will be fireside chats, with live webcasts and 30-day replays available via the company’s investor relations website.
Editas Medicine (Nasdaq: EDIT) reported second quarter 2026 results and business updates, highlighting progress of its in vivo CRISPR candidate EDIT-401 for hyperlipidemia and Heterozygous Familial Hypercholesterolemia. The company is on track to submit an Australian Clinical Trial Notification in August 2026 and plans to start a two-part Phase 1/2 trial, with a data update expected in Q1 2027 and Part 1 topline data in 2027.
Preclinical non-human primate data showed ~90% or greater mean reductions in LDL-C, Lp(a), and ApoB with a single EDIT-401 dose, sustained for about six months with no adverse clinical observations at 1.5 mg/kg. Editas completed a $125 million public equity and warrant offering, with potential additional gross proceeds of ~$194.4 million upon full warrant exercise. Cash and equivalents rose to $211.6 million at June 30, 2026, extending cash runway into the second half of 2028. Q2 2026 net loss narrowed to $18.2 million ($0.15 per share) from $53.2 million ($0.63) a year earlier, as revenue increased to $11.9 million and restructuring and impairment shifted to a $1.3 million benefit.
Editas Medicine (Nasdaq: EDIT) appointed Patrick T. Ellinor, M.D., Ph.D., to its Board of Directors, effective August 6, 2026, while Elliott Levy, M.D., will step down as an independent director. According to Editas, Dr. Ellinor is a recognized leader in cardiovascular medicine and human genetics whose work has identified novel therapeutic targets and advanced translation of genetic discoveries into potential therapies.
He currently serves as Executive Director of the Mass General Brigham Heart and Vascular Institute and Director of the Cardiovascular Disease Initiative at the Broad Institute. Editas highlighted that his expertise in integrating genetics, genomics, AI, and therapeutic discovery is expected to support advancement of EDIT-401 for the potential treatment of hyperlipidemia and the company’s in vivo gene editing platform.
Editas Medicine (Nasdaq: EDIT) updated the timing of its appearance at the 2026 Jefferies Global Healthcare Conference. The company will now present on June 4, 2026 at 2:00 p.m. ET in New York, with a live webcast and 30-day replay via its investor website.
Editas Medicine (Nasdaq: EDIT) priced an underwritten public offering of 55,555,556 common shares plus accompanying warrants to purchase 55,555,556 shares at a combined price of $2.25 per unit, for expected gross proceeds of about $125 million before expenses.
The common stock warrants are immediately exercisable at $3.50 per share (or $3.4999 for pre-funded warrants) and could generate up to an additional $194.4 million in gross proceeds if fully exercised. The offering, sold entirely by Editas Medicine, is expected to close on or about May 27, 2026, subject to customary conditions.
Editas Medicine (Nasdaq: EDIT) commenced a proposed underwritten public offering of common stock (or pre-funded warrants) and accompanying warrants, with all securities sold by the company.
The offering, managed by Cantor and Wells Fargo Securities, uses an effective Form S-3 shelf registration and is subject to market conditions, with final size and terms not yet set.
Editas Medicine (Nasdaq: EDIT) reported new preclinical data for its in vivo gene-editing candidate EDIT-401 presented at the 94th European Atherosclerosis Society Congress.
A single dose in non-human primates produced ~≥90% mean reductions in LDL-C, Lp(a), and ApoB, with rapid, dose-dependent effects and highly correlated changes linked to LDLR upregulation.
Editas is running GLP toxicology studies, reporting EDIT-401 was well-tolerated at 1.5 mg/kg, and received positive FDA pre-IND feedback. The company plans an Australian CTN by mid-2026 and aims for early in vivo human proof-of-concept data by end-2026.
Editas Medicine (Nasdaq: EDIT) reported new preclinical data for EDIT-401, its in vivo CRISPR candidate for hyperlipidemia, at the 2026 ASGCT and TIDES meetings. A single dose in non-human primates produced ≥90% mean LDL-C reduction with ≥6-fold hepatic LDLR increase and maintained LDL-C lowering for ~6 months across 1.5–3.0 mg/kg.
According to the company, EDIT-401 showed a promising preclinical safety profile at 1.5 mg/kg, hepatocyte-targeted delivery with undetectable oocyte delivery, and dose-dependent LDL-C reduction. Mouse data with EDIT-401(mu) suggest dose adjustments may not be needed for HeFH patients. DNA-LLM models also supported broader in vivo upregulation applications.